Epigallocatechin-3-gallate: A phytochemical as a promising drug candidate for the treatment of Parkinson’s disease
Epigallocatechin 3-gallate (EGCG), an abundant polyphenolic component derived from green tea extract, possesses versatile bioactivities that can combat many diseases. During the last decade, EGCG was shown to be effective in experimental models of Parkinson’s disease (PD). Several experimental studi...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.977521/full |
| _version_ | 1798002909997170688 |
|---|---|
| author | Yumin Wang Shuang Wu Qiang Li Weihong Lang Wenjing Li Xiaodong Jiang Zhirong Wan Jichao Chen Hongquan Wang |
| author_facet | Yumin Wang Shuang Wu Qiang Li Weihong Lang Wenjing Li Xiaodong Jiang Zhirong Wan Jichao Chen Hongquan Wang |
| author_sort | Yumin Wang |
| collection | DOAJ |
| description | Epigallocatechin 3-gallate (EGCG), an abundant polyphenolic component derived from green tea extract, possesses versatile bioactivities that can combat many diseases. During the last decade, EGCG was shown to be effective in experimental models of Parkinson’s disease (PD). Several experimental studies have suggested that it has pleiotropic neuroprotective effects, which has enhanced the appeal of EGCG as a therapeutic strategy in PD. In this review, we compiled recent updates and knowledge of the molecular mechanisms underlying the neuroprotective effects of EGCG in PD. We focused on the effects of EGCG on apoptosis, oxidative stress, inflammation, ferroptosis, modulation of dopamine production, and the aggregation of α-synuclein. The review highlights the pharmacological features of EGCG and its therapeutic implications in PD. Taken together, the accumulated data indicate that EGCG is a promising neuroprotective compound for the treatment of PD. |
| first_indexed | 2024-04-11T11:59:45Z |
| format | Article |
| id | doaj.art-793e6ac33d644ebcae9f5c64bc24a125 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-11T11:59:45Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-793e6ac33d644ebcae9f5c64bc24a1252022-12-22T04:24:53ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-09-011310.3389/fphar.2022.977521977521Epigallocatechin-3-gallate: A phytochemical as a promising drug candidate for the treatment of Parkinson’s diseaseYumin Wang0Shuang Wu1Qiang Li2Weihong Lang3Wenjing Li4Xiaodong Jiang5Zhirong Wan6Jichao Chen7Hongquan Wang8Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, ChinaDepartment of Neurology, Zhongnan Hospital of Wuhan University, Wuhan, ChinaDepartment of Neurology, The Affiliated Hospital of Chifeng University, Chifeng, ChinaDepartment of Psychological Medicine, The Affiliated Hospital of Chifeng University, Chifeng, ChinaDepartment of Neurology, The Affiliated Hospital of Chifeng University, Chifeng, ChinaDepartment of Anatomy, College of Basic Medicine, Chifeng University Health Science Center, Chifeng, ChinaDepartment of Neurology,Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, ChinaDepartment of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, ChinaTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, ChinaEpigallocatechin 3-gallate (EGCG), an abundant polyphenolic component derived from green tea extract, possesses versatile bioactivities that can combat many diseases. During the last decade, EGCG was shown to be effective in experimental models of Parkinson’s disease (PD). Several experimental studies have suggested that it has pleiotropic neuroprotective effects, which has enhanced the appeal of EGCG as a therapeutic strategy in PD. In this review, we compiled recent updates and knowledge of the molecular mechanisms underlying the neuroprotective effects of EGCG in PD. We focused on the effects of EGCG on apoptosis, oxidative stress, inflammation, ferroptosis, modulation of dopamine production, and the aggregation of α-synuclein. The review highlights the pharmacological features of EGCG and its therapeutic implications in PD. Taken together, the accumulated data indicate that EGCG is a promising neuroprotective compound for the treatment of PD.https://www.frontiersin.org/articles/10.3389/fphar.2022.977521/fullParkinson’s diseaseepigallocatechin 3-gallateoxidative stressapoptosisneuroinflammationα-synuclein |
| spellingShingle | Yumin Wang Shuang Wu Qiang Li Weihong Lang Wenjing Li Xiaodong Jiang Zhirong Wan Jichao Chen Hongquan Wang Epigallocatechin-3-gallate: A phytochemical as a promising drug candidate for the treatment of Parkinson’s disease Frontiers in Pharmacology Parkinson’s disease epigallocatechin 3-gallate oxidative stress apoptosis neuroinflammation α-synuclein |
| title | Epigallocatechin-3-gallate: A phytochemical as a promising drug candidate for the treatment of Parkinson’s disease |
| title_full | Epigallocatechin-3-gallate: A phytochemical as a promising drug candidate for the treatment of Parkinson’s disease |
| title_fullStr | Epigallocatechin-3-gallate: A phytochemical as a promising drug candidate for the treatment of Parkinson’s disease |
| title_full_unstemmed | Epigallocatechin-3-gallate: A phytochemical as a promising drug candidate for the treatment of Parkinson’s disease |
| title_short | Epigallocatechin-3-gallate: A phytochemical as a promising drug candidate for the treatment of Parkinson’s disease |
| title_sort | epigallocatechin 3 gallate a phytochemical as a promising drug candidate for the treatment of parkinson s disease |
| topic | Parkinson’s disease epigallocatechin 3-gallate oxidative stress apoptosis neuroinflammation α-synuclein |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.977521/full |
| work_keys_str_mv | AT yuminwang epigallocatechin3gallateaphytochemicalasapromisingdrugcandidateforthetreatmentofparkinsonsdisease AT shuangwu epigallocatechin3gallateaphytochemicalasapromisingdrugcandidateforthetreatmentofparkinsonsdisease AT qiangli epigallocatechin3gallateaphytochemicalasapromisingdrugcandidateforthetreatmentofparkinsonsdisease AT weihonglang epigallocatechin3gallateaphytochemicalasapromisingdrugcandidateforthetreatmentofparkinsonsdisease AT wenjingli epigallocatechin3gallateaphytochemicalasapromisingdrugcandidateforthetreatmentofparkinsonsdisease AT xiaodongjiang epigallocatechin3gallateaphytochemicalasapromisingdrugcandidateforthetreatmentofparkinsonsdisease AT zhirongwan epigallocatechin3gallateaphytochemicalasapromisingdrugcandidateforthetreatmentofparkinsonsdisease AT jichaochen epigallocatechin3gallateaphytochemicalasapromisingdrugcandidateforthetreatmentofparkinsonsdisease AT hongquanwang epigallocatechin3gallateaphytochemicalasapromisingdrugcandidateforthetreatmentofparkinsonsdisease |